Methods for artificially controlling the blood-brain barrier function - Overcoming refractory neurological disorders.
We have discovered functional molecules that artificially and reversibly open and close the blood-brain barrier.
*Looking for partner companies for joint development* The blood-brain barrier (BBB) has an important function in preventing harmful substances from entering the brain and maintaining a healthy environment within it. However, due to the presence of the BBB, water-soluble drugs administered peripherally cannot be delivered to the brain, and conversely, it has not been possible to restore the function of the BBB once it has opened due to pathological conditions such as neurodegenerative diseases. Recently, Yamaguchi University has established a method to artificially and reversibly open and close the BBB. By identifying the key factors involved in the opening and closing of the BBB and utilizing its physiological functions, it is now possible to reversibly open the BBB under conditions with minimal concerns about side effects, paving the way for drug delivery to the brain, which has been challenging. Additionally, restoring the function of the pathologically opened BBB is expected to improve disease conditions. <Target Diseases> - Closing an opened BBB: cerebral infarction, diabetic retinopathy, Alzheimer's disease, Parkinson's disease, etc. - Opening a closed BBB: brain tumors, neurological diseases, etc. <Benefits for Companies> - The development of new, highly safe therapeutic drugs is now possible through a novel mechanism that allows for the artificial and reversible opening and closing of the BBB.
Inquire About This Product
basic information
The novelty of the present invention lies in the method that utilizes the physiological regulatory mechanisms that brain vascular endothelial cells possess to regulate blood-brain barrier function. As a result, there is an advantage in that damage is minimized not only to vascular endothelial cells but also to neural tissue. Japanese Patent 6430371, European Patent 2990043 (English, French, German) Japanese Patent 6818358 Application No. 2020-139886 Application No. 2021-052018
Price range
Delivery Time
Applications/Examples of results
【Application Areas】 - Drug delivery adjuvants for neurological diseases such as Parkinson's disease and Alzheimer's disease - Tools for the development of treatments for neurological diseases
catalog（3）
Download All Catalogs
Company information
Yamaguchi TLO Co., Ltd. is a TLO approved by the Ministry of Education, Culture, Sports, Science and Technology and the Ministry of Economy, Trade and Industry based on the Act on the Promotion of Technology Transfer from Universities, established in November 1999 with investments from 50 faculty members of Yamaguchi University (capital of 4 million yen) before incorporation. It is a liaison-type technology transfer organization that bridges people. We return the research results from the university to society in the form of technology transfer and other means. Additionally, we are actively recruiting member companies to prioritize the disclosure of invention information and contribute to the development of the local economy through these efforts.
![[CPhI Seminar Report] Mutagenic Impurities in Pharmaceuticals (Active Pharmaceutical Ingredients)](https://image.mono.ipros.com/public/product/image/86f/2000714763/IPROS54094091646706511898.png?w=280&h=280)
![[Research Material] Global Market for Pediatric Respiratory Disease Treatment](https://image.mono.ipros.com/public/product/image/bdc/2001467329/IPROS87698443006144612309.jpeg?w=280&h=280)
![[Column] Management Strategies for Starting Materials in Active Pharmaceutical Ingredients](https://image.mono.ipros.com/public/product/image/3e5/2000710289/IPROS06292587954207697823.png?w=280&h=280)
